According to Zacks, “ANAVEX LIFE SCIENCES CORP. is an emerging biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases. The company’s proprietary SIGMACEPTOR Discovery Platform involves the rational drug design of compounds that fulfill specific criteria based on unmet market needs and new scientific advances. Selected drug candidates demonstrate high, non-exclusive affinity for sigma receptors, which are involved in the modulation of multiple cellular biochemical signaling pathways. “
Other analysts have also recently issued research reports about the stock. StockNews.com started coverage on shares of Anavex Life Sciences in a research note on Thursday, March 31st. They issued a “sell” rating on the stock. HC Wainwright restated a “buy” rating and issued a $42.00 target price on shares of Anavex Life Sciences in a report on Wednesday, March 16th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Anavex Life Sciences has a consensus rating of “Buy” and a consensus target price of $32.46.
Anavex Life Sciences (NASDAQ:AVXL – Get Rating) last announced its quarterly earnings results on Tuesday, May 10th. The biotechnology company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.03. During the same quarter in the previous year, the firm posted ($0.12) earnings per share. On average, research analysts forecast that Anavex Life Sciences will post -0.87 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently made changes to their positions in AVXL. FinTrust Capital Advisors LLC purchased a new stake in Anavex Life Sciences during the third quarter valued at approximately $44,000. Point72 Hong Kong Ltd purchased a new stake in Anavex Life Sciences during the third quarter valued at approximately $64,000. Apella Capital LLC purchased a new stake in Anavex Life Sciences during the first quarter valued at approximately $124,000. Teacher Retirement System of Texas purchased a new stake in Anavex Life Sciences during the third quarter valued at approximately $182,000. Finally, HighTower Advisors LLC lifted its position in Anavex Life Sciences by 21.2% during the fourth quarter. HighTower Advisors LLC now owns 10,278 shares of the biotechnology company’s stock valued at $178,000 after acquiring an additional 1,800 shares during the last quarter. 29.01% of the stock is owned by hedge funds and other institutional investors.
Anavex Life Sciences Company Profile (Get Rating)
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex.
- Get a free copy of the StockNews.com research report on Anavex Life Sciences (AVXL)
- Zoom Video Communications Is Primed To Launch Higher
- Fundamental Strength Makes Williams-Sonoma One for Your Recovery Watchlist
- Veeva Systems: Increasing NDR and Other Wins
- Institutions Buy The Dip In Petco Health and Wellness Company
- Autozone Edges Past Advanced Auto Parts In Q1 2022
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.